1-4 of 4
Jiangtao Ren
Close
Sort by
Journal Articles

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Yongxian Hu, Mingming Zhang, Tingting Yang, Ruirui Jing, Houli Zhao, Rongrong Chen, Tianning Gu, Pingnan Xiao, Ruimin Hong, Jingjing Feng, Shan Fu, Delin Kong, Huijun Xu, Jiazhen Cui, Simao Huang, Bin Liang, Guoqing Wei, Xiaolin Yuan, Qu Cui, Jiangtao Ren, Alex H. Chang, Dongrui Wang, He Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 1039.
https://doi.org/10.1182/blood-2023-185697
Published: 2023
Journal Articles

A Novel Universal CD7-Targeted CAR-T Cell Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma

Xian Zhang, Yali Zhou, Junfang Yang, Jingjing Li, Liyuan Qiu, Wengang Ge, Bo Pei, Jie Chen, Lu Han, Jiangtao Ren, Peihua Lu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4566–4567.
https://doi.org/10.1182/blood-2022-165733
Published: 2022
Journal Articles

The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Yongxian Hu, MD, Yali Zhou, Mingming Zhang, MD, Wengang Ge, Yi Li, MD, Li Yang, MD, Guoqing Wei, MD, Lu Han, Hao Wang, Xingwang Zhang, PhD, Jiangtao Ren, PhD, He Huang, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52.
https://doi.org/10.1182/blood-2020-142262
Published: 2020
Journal Articles

Multiplex Cripsr/Cas9 Genome Editing to Generate Potent Universal CART and PD1-Deficient Cells Against Leukemia

Jiangtao Ren, PhD, Xiaojun Liu, Master, Chongyun Fang, PhD, Shuguang Jiang, PhD, Carl H. June, MD, Yangbing Zhao, PhD MD
Journal: Blood
Blood (2015) 126 (23): 4280.
https://doi.org/10.1182/blood.V126.23.4280.4280
Published: 2015